Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
UGDH promotes tumor-initiating cells and a fibroinflammatory tumor microenvironment in ovarian cancer.
Harrington BS, Kamdar R, Ning F, Korrapati S, Caminear MW, Hernandez LF, Butcher D, Edmondson EF, Traficante N, Hendley J; Australian Ovarian Cancer Study; Gough M, Rogers R, Lourie R, Shetty J, Tran B, Elloumi F, Abdelmaksoud A, Nag ML, Mazan-Mamczarz K, House CD, Hooper JD, Annunziata CM. Harrington BS, et al. Among authors: lourie r. J Exp Clin Cancer Res. 2023 Oct 19;42(1):270. doi: 10.1186/s13046-023-02820-z. J Exp Clin Cancer Res. 2023. PMID: 37858159 Free PMC article.
CDCP1 enhances Wnt signaling in colorectal cancer promoting nuclear localization of β-catenin and E-cadherin.
He Y, Davies CM, Harrington BS, Hellmers L, Sheng Y, Broomfield A, McGann T, Bastick K, Zhong L, Wu A, Maresh G, McChesney S, Yau Wong K, Adams MN, Sullivan RC, Palmer JS, Burke LJ, Ewing AD, Zhang X, Margolin D, Li L, Lourie R, Matsika A, Srinivasan B, McGuckin MA, Lumley JW, Hooper JD. He Y, et al. Among authors: lourie r. Oncogene. 2020 Jan;39(1):219-233. doi: 10.1038/s41388-019-0983-3. Epub 2019 Aug 30. Oncogene. 2020. PMID: 31471585
Anti-CDCP1 immuno-conjugates for detection and inhibition of ovarian cancer.
Harrington BS, He Y, Khan T, Puttick S, Conroy PJ, Kryza T, Cuda T, Sokolowski KA, Tse BW, Robbins KK, Arachchige BJ, Stehbens SJ, Pollock PM, Reed S, Weroha SJ, Haluska P, Salomon C, Lourie R, Perrin LC, Law RHP, Whisstock JC, Hooper JD. Harrington BS, et al. Among authors: lourie r. Theranostics. 2020 Jan 12;10(5):2095-2114. doi: 10.7150/thno.30736. eCollection 2020. Theranostics. 2020. PMID: 32104500 Free PMC article.
Disruption of Glycogen Utilization Markedly Improves the Efficacy of Carboplatin against Preclinical Models of Clear Cell Ovarian Carcinoma.
Khan T, He Y, Kryza T, Harrington BS, Gunter JH, Sullivan MA, Cuda T, Rogers R, Davies CM, Broomfield A, Gough M, Wu AC, McGann T, Weroha SJ, Haluska P, Forbes JM, Armes JE, Barry SC, Coward JI, Jagasia N, Chetty N, Snell CE, Lourie R, Perrin LC, Hooper JD. Khan T, et al. Among authors: lourie r. Cancers (Basel). 2020 Apr 3;12(4):869. doi: 10.3390/cancers12040869. Cancers (Basel). 2020. PMID: 32260077 Free PMC article.
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer.
He Y, Khan T, Kryza T, Jones ML, Goh JB, Lyons NJ, Pearce LA, Lee MD, Gough M, Rogers R, Davies CM, Gilks CB, Hodgkinson T, Lourie R, Barry SC, Perrin LC, Williams CC, Puttick S, Adams TE, Munro TP, Hooper JD, Chetty N. He Y, et al. Among authors: lourie r. Mol Pharm. 2021 Sep 6;18(9):3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401. Epub 2021 Aug 27. Mol Pharm. 2021. PMID: 34448393
149 results